Supersymmetric Many-particle Quantum Systems with Inverse-square Interactions

The development in the study of supersymmetric many-particle quantum systems with inverse-square interactions is reviewed. The main emphasis is on quantum systems with dynamical OSp(2|2) supersymmetry. Several results related to exactly solved supersymmetric rational Calogero model, including shape invariance, equivalence to a system of free superoscillators and non-uniqueness in the construction of the Hamiltonian, are presented in some detail. This review also includes a formulation of pseudo-hermitian supersymmetric quantum systems with a special emphasis on rational Calogero model. There are quite a few number of many-particle quantum systems with inverse-square interactions which are not exactly solved for a complete set of states in spite of the construction of infinitely many exact eigen functions and eigenvalues. The Calogero-Marchioro model with dynamical SU(1,1|2) supersymmetry and a quantum system related to short-range Dyson model belong to this class and certain aspects of these models are reviewed. Several other related and important developments are briefly summarized.Comment: LateX, 65 pages, Added Acknowledgment, Discussions and References, Version to appear in Jouranl of Physics A: Mathematical and Theoretical (Commissioned Topical Review Article

Liquid Chromatography–Mass Spectrometry Method for The Analysis of The Anti-Cancer Agent Capecitabine and Its Nucleoside Metabolites in Human Plasma

A reversed-phase high-performance liquid chromatography method with electrospray ionization and mass spectral detection is described for the determination of capecitabine, 5′-deoxy-5-fluorocytidine and 5′-deoxy-5-fluorouridine in human plasma with 5-chloro-2′-deoxyuridine as the internal standard. An on-line sample clean-up procedure allows dilution of the plasma sample with the initial mobile phase. The linear dynamic range is 0.0500–10.0 μg/ml for capecitabine, and 0.0500–25.0 μg/ml for the metabolites, 5′-deoxy-5-fluorocytidine and 5′-deoxy-5-fluorouridine, respectively. This method has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin

Liquid Chromatography–Mass Spectrometry Method for The Analysis of The Anti-Cancer Agent Capecitabine and Its Nucleoside Metabolites in Human Plasma

A reversed-phase high-performance liquid chromatography method with electrospray ionization and mass spectral detection is described for the determination of capecitabine, 5′-deoxy-5-fluorocytidine and 5′-deoxy-5-fluorouridine in human plasma with 5-chloro-2′-deoxyuridine as the internal standard. An on-line sample clean-up procedure allows dilution of the plasma sample with the initial mobile phase. The linear dynamic range is 0.0500–10.0 μg/ml for capecitabine, and 0.0500–25.0 μg/ml for the metabolites, 5′-deoxy-5-fluorocytidine and 5′-deoxy-5-fluorouridine, respectively. This method has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.

We recently demonstrated original anti-tumor effects of zoledronic acid (Zol) on osteosarcoma cell lines independently of their p53 and Rb status. The present study investigated the potential Zol-resistance acquired by osteosarcoma cells after prolonged treatment. After 12 weeks of culture in the presence of 1 microm Zol, the effects of high doses of Zol (10-100 microm) were compared between the untreated rat (OSRGA, ROS) and human (MG63, SAOS2) osteosarcoma cells and Zol-pretreated cells in terms of cell proliferation, cell cycle analysis, migration assay and cytoskeleton organization. Long-term treatment with 1 microm Zol reduced the sensitivity of osteosarcoma cells to high concentrations of Zol. Furthermore, the Zol-resistant cells were sensitive to conventional anti-cancer agents demonstrating that this resistance process is independent of the multidrug resistance phenotype. However, as similar experiments performed in the presence of clodronate and pamidronate evidenced that this drug resistance was restricted to the nitrogen-containing bisphosphonates, we then hypothesized that this resistance could be associated with a differential expression of farnesyl diphos-phate synthase (FPPS) also observed in human osteosarcoma samples. The transfection of Zol-resistant cells with FPPS siRNA strongly increased their sensitivity to Zol. This study demonstrates for the first time the induction of metabolic resistance after prolonged Zol treatment of osteosarcoma cells confirming the therapeutic potential of Zol for the treatment of bone malignant pathologies, but points out the importance of the treatment regimen may be important in terms of duration and dose to avoid the development of drug metabolic resistance

Measurement of the Anticancer Agent Gemcitabine and Its Deaminated Metabolite at Low Concentrations in Human Plasma by Liquid Chromatography-Mass Spectrometry

A liquid chromatography/mass spectrometry (LC-MS) method has been developed and validated for the determination of the anticancer agent gemcitabine (dFdC) and its metabolite 2′,2′-difluoro-2′-deoxyuridine (dFdU) in human plasma. An Oasis® HLB solid phase extraction cartridge was used for plasma sample preparation. Separation of the analytes was achieved with a YMC ODS-AQ (5 μm, 120 Å, mm) column. The initial composition of the mobile phase was 2% methanol/98% 5 mM ammonium acetate at pH 6.8 (v/v), and the flow rate was 0.2 ml/min. An isocratic gradient was used for 3 min, followed by a linear gradient over 4 min to 30% methanol/70% 5 mM ammonium acetate at pH 6.8. The gradient returned to the initial conditions over 2 min and remained there for 6 min. The retention times of dFdC, dFdU, and the internal standard 5′-deoxy-5-fluorouridine (5′-DFUR) were 11.46, 12.63, and 13.58 min. The mass spectrometer was operated under negative electrospray ionization conditions. Single-ion-monitoring (SIM) mode was used for analyte quantitation at m/z 262 for [dFdC–H]−, m/z 263 for [dFdU–H]−, and m/z 245 for [5′-DFUR–H]−. The average recoveries for dFdC, dFdU, and 5′-DFUR were 88.4, 84.6, and 99.3%, respectively. The linear calibration ranges were 5–1000 ng/ml for dFdC, and 5–5000 ng/ml for dFdU. The intra- and inter-assay precisions (%CV) were ≤3 and ≤7% at three concentration levels (50.0, 500, and 5000 ng/ml). The limits of quantitation (defined as 10 times of signal-to-noise ratio) were 3.16 ng/ml for dFdC, and 1.35 ng/ml for dFdU with 50-μl sample injections. This method has been used for measuring plasma concentrations of dFdC and dFdU in samples from adult cancer patients in a Phase I trial of weekly dFdC given as 150 (or lower) mg/(m2 24-h) infusion. The average plasma dFdC concentrations at 22- and 23-h into the infusion were 18.3 and 16.8 ng/ml at 150 and 100 mg/m2, respectively; the values for dFdU averaged 2950 and 1372 ng/ml

Measurement of the Anti-Cancer Agent Gemcitabine in Human Plasma by High-Performance Liquid Chromatography

A reversed-phase HPLC assay has been developed to determine the concentration of the anti-metabolite 2′,2′-difluorodeoxycytidine (gemcitabine, dFdC) in human plasma over the concentration range of 0.5–150 μM (0.13–39.44 μg/ml), and 2′,2′-difluorodeoxyuridine (dFdU), the deaminated, inactive metabolite, over the range of 1.0–227 μM (0.26–60 μg/ml). After the addition of 20 nmol 2′-fluorodeoxycytidine (FdC) as an internal standard, 0.5-ml samples of plasma were subjected to acetonitrile precipitation, followed by analysis using a gradient reversed-phase HPLC assay with UV detection. A Phenomenex Columbus™ C18 column, 5 μm, 150×4.6 mm, and a Waters C18, 4 μm, Nova-Pak Sentry guard column were used to achieve separation. FdC, dFdC and dFdU were monitored at 282, 269 and 258 nm, respectively, on a Waters 996 photodiode array detector. The mobile phase, run at a total flow-rate of 1.5 ml/min, was composed of two solvents: 50 mM ammonium acetate pH 5.0 in either 2% (solvent A) or 10% methanol (solvent B, v/v); 100% solvent A was run for 17 min, followed by a linear gradient to 100% solvent B over 14 min. FdC, dFdC and dFdU were resolved from endogenous compounds and had retention times of 13.6±0.5, 18.1±1.1 and 29.0±0.6 min, respectively. The assay was useful in measuring the plasma levels of both analytes in samples obtained from adult cancer patients participating in a Phase I trial of gemcitabine given as either a 1- or 2-h infusion weekly for 3 of 4 weeks

The South of the Mind: American Imaginings of White Southernness, 1960-1980

A roundtable discussion among Zachary J. Lechner, Darren Grem, and Margaret T. McGehee about Lechner\u27s book, The South of the Mind: American Imaginings of White Southernness, 1960-1980 (U of Georgia Press, 2018).https://egrove.olemiss.edu/studythesouth/1011/thumbnail.jp

Solid-state-concentration effects on the optical absorption and emission of poly(p-phenylene vinylene)-related materials

We present measurements of the optical absorption and emission properties of poly(p-phenylene vinylene) (PPV)-related materials focusing on the differences between molecules isolated by dispersion in an inert host and concentrated molecular films. Optical absorption spectra, photoluminescence (PL) spectra, PL efficiency, and time-resolved PL spectra of dilute blends of PPV oligomers with 2-5 phenylene-phenyl rings are compared with those of dense oligomer and polymer films. In dilute oligomer-poly(methyl methacrylate) (PMMA) blends with high PL efficiency, the PL decay is exponential, independent of both temperature and oligomer length. This implies that the fundamental radiative lifetime of PPV oligomers is essentially independent of oligomer length. Concentrated spin-cast oligomer films and polymers have a faster and strongly temperature-dependent PL decay that approaches that of the dilute oligomer results at low temperature. The differences in PL decay correspond to changes in PL efficiency. The efficiency of the oligomer-PMMA blend is high and only weakly temperature dependent, whereas that of concentrated films is lower and strongly temperature dependent, decreasing by more than a factor of 3 from 10 to 350 K. The quenching of the PL efficiency in concentrated films is due to migration to extrinsic, impurity related centers as opposed to an intrinsic intermolecular recombination process. The PL spectrum of a dilute oligomer blend redshifts substantially, both as the excitation energy is decreased and as the emission time increases. This spectral redshift is due to disorder-induced site-to-site variation and not to diffusion to lower-energy sites. In contrast, no spectral shift with excitation energy or emission time was observed for dense oligomer films